Axxam enters CNS partnership with Lundbeck for Lead Identification

We announce the formalization of a partnership with Lundbeck A/S, aimed at supporting Lundbeck for early-stage drug discovery programs related to CNS indications.

The signature of this first partnership agreement between Axxam and Lundbeck, for the identification and qualification of small molecules relevant to CNS targets, comes after more than five years of successful collaboration in assay development and High-Throughput Screening.

Scroll to Top